公开(公告)号：US20180003710A1

公开(公告)日：2018-01-04

申请号：US15673976

申请日：2017-08-10

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Stefan Weiser ,  Johann Karl ,  Ursula Kunert ,  Florian Grupp

IPC: G01N33/564 ,  G01N33/563 ,  G01N33/58

CPC classification number: G01N33/564 ,  G01N33/563 ,  G01N33/58 ,  G01N2333/91215 ,  G01N2800/102

Abstract: The present invention relates to a method aiding in the assessment of rheumatoid arthritis (“RA”). The method is used in assessing RA in vitro. It is practiced by analyzing biochemical markers, comprising measuring the concentration of anti-CCP and anti-PIK3CD and correlating the concentrations determined to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and anti-PIK3CD in the diagnosis of RA and it teaches a kit for performing the method of the invention. Further the invention relates to the use of a marker panel comprising anti-CCP and anti-PIK3CD to differentiate RA from other autoimmune diseases, preferably osteoarthritis (OA).

公开(公告)号：US20160109461A1

公开(公告)日：2016-04-21

申请号：US14919456

申请日：2015-10-21

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Julia Riedlinger ,  Norbert Wild

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/6884 ,  G01N2333/914 ,  G01N2333/916 ,  G01N2800/122 ,  G01N2800/60

Abstract: An in vitro method aiding in the assessment of chronic obstructive pulmonary disease (COPD). The disclosure further relates to a method for assessing COPD from a sample, derived from an individual, by measuring the protein FEN1 in said sample in vitro.

Abstract translation: 一种协助慢性阻塞性肺疾病（COPD）评估的体外方法。 本公开还涉及通过在体外测量所述样品中的蛋白质FEN1来评估来自个体的样品的COPD的方法。

公开(公告)号：US20150126401A1

公开(公告)日：2015-05-07

申请号：US14598630

申请日：2015-01-16

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Norbert Wild ,  Ursula Garczarek

IPC: G01N33/574

CPC classification number: G01N33/57419 ,  G01N33/721 ,  G01N2333/4727 ,  G01N2333/805

Abstract: The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention.

Abstract translation: 本发明涉及一种协助评估结肠直肠癌的方法。 该方法特别用于评估体外存在或不存在结肠直肠癌。 该方法例如通过分析生物化学标记来实施，包括在粪便样品中测量血红蛋白/触珠蛋白复合物和钙卫蛋白的浓度，并将确定的浓度与不存在或存在结肠直肠癌相关联。 为了进一步改进基于本发明方法的结肠直肠癌的评估，可以在粪便样品中与血红蛋白/触珠蛋白复合物和钙卫蛋白一起测定一种或多种另外的标记物的水平，并与结肠直肠癌的存在或不存在相关 。 本发明还涉及包含血红蛋白/触珠蛋白复合物和钙卫蛋白的标记物在早期诊断结肠直肠癌中的用途，并且其教导了用于实施本发明方法的试剂盒。

公开(公告)号：US20150072355A1

公开(公告)日：2015-03-12

申请号：US14529702

申请日：2014-10-31

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Norbert Wild ,  Marie-Luise Hagmann ,  Johann Karl ,  Julia Riedlinger ,  Markus Roessler ,  Michael Tacke

IPC: G01N33/543 ,  G06F19/00

CPC classification number: G01N33/573 ,  G01N33/54306 ,  G01N33/57411 ,  G01N33/57415 ,  G01N33/57419 ,  G01N33/57423 ,  G01N33/5743 ,  G01N33/57434 ,  G01N33/57438 ,  G01N33/57442 ,  G01N33/57449 ,  G01N33/57488 ,  G01N2333/922 ,  G01N2800/52 ,  G01N2800/7028 ,  G16H50/30 ,  Y02A90/26

Abstract: Methods aiding in the assessment of cancer comprising use of the Flap endonuclease-1 protein (=FEN1) as a universal marker of different cancer types are provided. In particular, methods for assessing cancer from a liquid sample derived from an individual, which comprise measuring FEN1 in the sample are disclosed. Measurement of FEN1 is useful for the early detection of cancer or in the monitoring of patients who undergo surgery for tumor removal.

Abstract translation: 提供了帮助评估癌症的方法，包括使用Flap核酸内切酶-1蛋白（= FEN1）作为不同癌症类型的通用标记。 特别地，公开了从样品中得到的来自个体的液体样品中评估癌症的方法，其包括测量样品中的FEN1。 FEN1的测量可用于癌症的早期检测或用于手术切除肿瘤的患者的监测。

公开(公告)号：US11644472B2

公开(公告)日：2023-05-09

申请号：US16217612

申请日：2018-12-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Dirk Block ,  Johann Karl ,  Peter Kastner ,  Ursula-Henrike Wienhues-Thelen ,  Roberto Latini ,  Serge Masson ,  Andre Ziegler ,  Edelgard Kaiser ,  Stefan Palme ,  Markus Thomas ,  Simona Barlera

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/6887 ,  G01N33/6893 ,  G01N2800/326

Abstract: A method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject is described. Also described is a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Also described are devices adapted to carry out the method of the present disclosure.

公开(公告)号：US11047866B2

公开(公告)日：2021-06-29

申请号：US16420385

申请日：2019-05-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Christian Zaugg ,  Hans-Peter Brunner ,  James Januzzi ,  Andre Ziegler ,  Julian Braz ,  Thomas Dieterle ,  Edelgard Kaiser

IPC: G01N33/53 ,  G01N33/68

Abstract: Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.

公开(公告)号：US20210190801A1

公开(公告)日：2021-06-24

申请号：US17177673

申请日：2021-02-17

Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC. ,  UNIVERSITEIT MAASTRICHT ,  ACADEMISCH ZIEKENHUIS MAASTRICT

Inventor： Johann Karl ,  Peter Kastner ,  Ursula-Henrike Wienhues-Thelen ,  Manuel Dietrich ,  Andre Ziegler ,  Ulrich Schotten

IPC: G01N33/68 ,  G01N33/577

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP 10 in a sample from the subject, and comparing the amount of BMP 10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP 10-type peptide in a sample from a subject.

公开(公告)号：US20210132085A1

公开(公告)日：2021-05-06

申请号：US17150504

申请日：2021-01-15

Applicant: GENENTECH, INC. ,  Roche Diagnostics Operations, Inc.

Inventor： Tobias Bittner ,  Johann Karl ,  Valeria Lifke ,  Verena Steffen ,  Martina Jocham

IPC: G01N33/68 ,  G01N33/577

Abstract: The present disclosure relates to identifying an individual as having or being at risk of developing an amyloid-positive dementia based on marker molecules amyloid β40 (Aβ40), amyloid β42 (Aβ42) and total Tau (tTau), the use of the marker molecules for the identification of an individual having or being at risk of developing an amyloid-positive dementia and a method for detecting an individual with an increased value for the combination of the marker molecules.

公开(公告)号：US20170010283A1

公开(公告)日：2017-01-12

申请号：US15274533

申请日：2016-09-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Christian Zaugg ,  Hans-Peter Brunner ,  James Januzzi ,  Andre Ziegler ,  Julian Braz ,  Thomas Dieterle ,  Edelgard Kaiser

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/6887 ,  G01N2333/47 ,  G01N2800/325

Abstract: The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.

Abstract translation: 本发明涉及一种用于诊断和/或分级舒张功能障碍或与舒张功能障碍相关的至少一种结构或功能异常的方法。 该方法包括测量患有心力衰竭的患者中IGFBP7（胰岛素样生长因子结合蛋白7）的水平和任选地至少一个其他标记物的水平，并将该水平与参考水平进行比较。 进一步设想的是监测患有心力衰竭的患者的舒张功能的方法。 本发明还包括适用于实施本发明方法的试剂盒和装置。

公开(公告)号：US11874282B2

公开(公告)日：2024-01-16

申请号：US16110687

申请日：2018-08-23

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Martin Hund ,  Edelgard Anna Kaiser ,  Ursula-Henrike Wienhues-Thelen ,  Dirk Block ,  Johann Karl

IPC: G01N31/00 ,  G01N33/53 ,  G01N33/68 ,  G16B99/00 ,  G16B20/00 ,  G16B25/10

CPC classification number: G01N33/689 ,  G01N33/6893 ,  G16B20/00 ,  G16B25/10 ,  G16B99/00 ,  G01N2333/4703 ,  G01N2333/4745 ,  G01N2800/368 ,  G01N2800/52 ,  G01N2800/60

Abstract: The present disclosure relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also disclosed are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present disclosure further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Finally, the present disclosure relates to a device or kit adapted to carry out the method of the present invention.